Market Research Logo

Marburg Hemorrhagic Fever - Pipeline Review, H2 2016

Marburg Hemorrhagic Fever - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Marburg Hemorrhagic Fever - Pipeline Review, H2 2016’, provides an overview of the Marburg Hemorrhagic Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Marburg Hemorrhagic Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Marburg Hemorrhagic Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Marburg Hemorrhagic Fever
  • The report reviews pipeline therapeutics for Marburg Hemorrhagic Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Marburg Hemorrhagic Fever therapeutics and enlists all their major and minor projects
  • The report assesses Marburg Hemorrhagic Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Marburg Hemorrhagic Fever
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Marburg Hemorrhagic Fever
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Marburg Hemorrhagic Fever pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Marburg Hemorrhagic Fever Overview
Therapeutics Development
Pipeline Products for Marburg Hemorrhagic Fever - Overview
Pipeline Products for Marburg Hemorrhagic Fever - Comparative Analysis
Marburg Hemorrhagic Fever - Therapeutics under Development by Companies
Marburg Hemorrhagic Fever - Therapeutics under Investigation by Universities/Institutes
Marburg Hemorrhagic Fever - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Marburg Hemorrhagic Fever - Products under Development by Companies
Marburg Hemorrhagic Fever - Products under Investigation by Universities/Institutes
Marburg Hemorrhagic Fever - Companies Involved in Therapeutics Development
Arno Therapeutics, Inc.
BioCryst Pharmaceuticals, Inc.
GeoVax Labs, Inc.
GlaxoSmithKline Plc
Integrated BioTherapeutics, Inc.
Johnson & Johnson
NanoViricides, Inc.
Profectus BioSciences, Inc.
Sarepta Therapeutics, Inc.
Marburg Hemorrhagic Fever - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(Ebola + Marburg) (monovalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Ebola + Marburg) (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Ebola + Marburg) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Ebola [Sudan, Zaire] + Marburg) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
1-E703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies for Ebola and Marburg Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARD-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVI-7288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-4430 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FDX-000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GOVXE-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GOVXE-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Marburg vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Marburg Virus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Glycoprotein for Ebola and Marburg Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nilotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Ebola and Marburg Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Ebola and Marburg Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Marburg Hemorrhagic Fever - Dormant Projects
Marburg Hemorrhagic Fever - Discontinued Products
Marburg Hemorrhagic Fever - Product Development Milestones
Featured News & Press Releases
Jul 22, 2015: Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus platform
Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate
Sep 17, 2013: BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases to Develop BCX4430 for the Treatment of Marburg Virus Disease
May 07, 2013: Sarepta Therapeutics Initiates Dosing In Phase I Multiple Ascending Dose Study Of Drug For Treatment Of Marburg Virus
Mar 04, 2013: Sarepta Therapeutics's Marburg Drug Shows High Survival Rates After Intramuscular Delivery In Non-Human Primates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Marburg Hemorrhagic Fever, H2 2016
Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Marburg Hemorrhagic Fever - Pipeline by Arno Therapeutics, Inc., H2 2016
Marburg Hemorrhagic Fever - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2016
Marburg Hemorrhagic Fever - Pipeline by GeoVax Labs, Inc., H2 2016
Marburg Hemorrhagic Fever - Pipeline by GlaxoSmithKline Plc, H2 2016
Marburg Hemorrhagic Fever - Pipeline by Integrated BioTherapeutics, Inc., H2 2016
Marburg Hemorrhagic Fever - Pipeline by Johnson & Johnson, H2 2016
Marburg Hemorrhagic Fever - Pipeline by NanoViricides, Inc., H2 2016
Marburg Hemorrhagic Fever - Pipeline by Profectus BioSciences, Inc., H2 2016
Marburg Hemorrhagic Fever - Pipeline by Sarepta Therapeutics, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Marburg Hemorrhagic Fever - Dormant Projects, H2 2016
Marburg Hemorrhagic Fever - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Marburg Hemorrhagic Fever, H2 2016
Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report